Anthony Gringeri | Anthony Gringeri | Anthony Gringeri

Anthony Gringeri Discussion started by Anthony Gringeri 12 months ago
Anthony Gringeri has been appointed Senior Vice President, Strategic Resources, reporting to Andrew Gengos, Chief Executive Officer. He will bring his wide range of expertise to bear on key functions, including project management, clinical development, regulatory affairs, business development, stakeholder relations and strategic planning.
Anthony Gringeri have more than 25 years of executive experience in the pharmaceutical and biotechnology industry, having successfully led multiple functions and cross-functional teams throughout his career, including in the areas of clinical, regulatory and commercial planning and operations, finance, licensing and alliance management.
In his prepared remarks brief on the Q4 results Anthony Gringeri said that he looks forward to taking question later in the call. Its been a longtime stockholder have been watching the progress, and know that these are the challenging times for the company.
“The partnering and other collaborative structures that could potentially strengthen standing in the immuno-oncology arena and enable to continue to advance towards creating a leading cancer immunotherapy company”said Anthony Gringeri for the strategic options in immunotherapy.
Anthony Gringeri will continue to pursue various avenues and acknowledge the pursuits for the commitment and seek opportunities to deliver value to all stakeholders, including patients and families affected by cancer, the medical and scientific communities whose interest in immunotherapy approaches remains strong.
Early on Dr. Anthony Gringeri was the Product Development Team Leader overseeing Amgen's blockbuster drug, ARANESP(R) (darbepoetin alfa), an erythropoiesis stimulating protein biologic drug (medicines whose active substance comes from a biological source).
Dr.Anthony Gringeri holds a Master's degree and a Ph.D. in Pharmacology from the University of Rochester. He has also published several articles in the field of biotechnology. He authored multiple scientific publications.
Most recently Dr. Anthony Gringeri served Amsterdam Molecular Therapeutics (AMT) as the Chief Operating Officer, which is a Netherlands-based company engaged in human gene therapies for orphan diseases. It related to metabolic disorders, liver diseases, blood diseases, and disorders of the central and peripheral nervous systems. He was responsible for the planning and execution of all major aspects of corporate strategy and operations in the AMT, including regulatory affairs.